UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
(Address of principal executive offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of Class | Trading Symbol | Name of Exchange on which Registered |
|---|---|---|
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01Entry into a Material Definitive Agreement.
On March 13, 2023, ReShape Lifesciences Inc. (the “Company”) entered into a lease (the “Lease”) with The Irvine Company LLC, a Delaware limited liability company (the “Landlord”), whereby the Company agreed to lease approximately 5,038 square feet at 18 Technology Drive, Suite 110, Irvine, California 92618. The Lease has a term of 36 months commencing on May 1, 2023. The Company intends to relocate its principal executive offices from its current San Clemente, California location to the Irvine, California location. The Company’s lease for its current facility expires on June 30, 2023. The relocation is expected to result in approximately $240,000 in annual cost savings related to the Company’s rent payments under its lease.
Under the Lease, the Company has agreed to pay rent, after an initial two month abatement period, in an initial amount equal to $9,068 per month, subject to subsequent scheduled increases. The Company will also be responsible for its pro rata share of operating expenses, including property taxes. The Lease contains customary representations, warranties, covenants, indemnification provisions, default provisions, and other provisions.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RESHAPE LIFESCIENCES INC. | ||
By: | /s/ Paul F. Hickey | |
Paul F. Hickey | ||
President and Chief Executive Officer | ||
Dated: March 21, 2023
Cover |
Mar. 13, 2023 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Document Period End Date | Mar. 13, 2023 |
| Entity File Number | 1-37897 |
| Entity Registrant Name | RESHAPE LIFESCIENCES INC. |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 26-1828101 |
| Entity Address, Address Line One | 1001 Calle Amanecer |
| Entity Address, City or Town | San Clemente |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 92673 |
| City Area Code | 949 |
| Local Phone Number | 429-6680 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common stock, $0.001 par value per share |
| Trading Symbol | RSLS |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Entity Central Index Key | 0001427570 |
| Amendment Flag | false |